| Document |
Document Title |
|
WO/2017/181303A1 |
A method for preparing active ingredients of Eurycoma longifolia and a use thereof. The preparation method comprises the following steps: at a given temperature, extracting Eurycoma longifolia by means of countercurrent ultrasound to obt...
|
|
WO/2017/179012A1 |
The present invention relates to a pharmaceutical or nutraceutical composition comprising at least one inositol and resveratrol for use in the a) preventive and/or curative treatment in the metabolic disorders related to polycystic ovary...
|
|
WO/2017/180174A1 |
The present disclosure provides compositions and methods for making and using topical compositions comprised of an isotonic, biome-friendly solution containing xylose and/or a Salvia extract. The compositions are useful for, for example,...
|
|
WO/2017/176938A1 |
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of bone morphogenetic protein receptor type II (BMPRII) polypeptide binds to ligands inc...
|
|
WO/2017/168174A1 |
The invention provides a pharmaceutical composition comprising sildenafil or a pharmaceutically acceptable salt thereof admixed with excipients in a multicomponent pharmaceutical composition, wherein a first component is adapted to deliv...
|
|
WO/2017/170564A1 |
[Problem] To provide a novel DDS having SN-38 as the medicinal component. [Solution] An excellent SN-38 ester derivative with cancer cell proliferation inhibitory activity is provided which is effective in nanodrug production.
|
|
WO/2017/170765A1 |
Provided are: a novel nitrogen-containing heterocyclic compound, which has an aldosterone synthase-inhibiting activity and, therefore, is useful for preventing and/or treating various diseases or symptoms associated with aldosterone and/...
|
|
WO/2017/163216A1 |
The present invention relates to a pharmaceutical composition or a composition for a medical device or a composition for a food supplement (briefly, the composition (s) of the present invention) based on lactic acid bacteria belonging to...
|
|
WO/2017/163217A1 |
The present invention relates to a pharmaceutical composition or a composition for a medical device or a composition for a food supplement (briefly, the composition (s) of the present invention) based on lactic acid bacteria belonging to...
|
|
WO/2017/161427A1 |
The present invention relates to a method for producing hybrid or non-hybrid recombinant glycoprotein hormones, for example the recombinant equine chorionic gonadotropin (r-eCG), the hybrid recombinant chorionic gonadotropin, the recombi...
|
|
WO/2017/162770A1 |
The invention relates to a product, in particular a nutritional supplement, animal feed, foodstuff, drug, cosmetic and/or animal feed supplement for supplying at least one molecule that bonds to a vitamin D receptor, in particular a calc...
|
|
WO/2017/161222A1 |
The invention is for methods and compositions for blocking calcium- activated channels in uterine smooth muscle tissue which in turn inhibits or blocks uterine contractions leading to preterm labor. This methods and compositions are usef...
|
|
WO/2017/157260A1 |
Provided are a phenylpropanoid and a preparation method and application thereof. The phenylpropanoid has a structure represented by formula (I), and a pharmaceutically acceptable salt thereof has a structure represented by formula (II) o...
|
|
WO/2017/153608A1 |
The invention relates to a zona pellucida (ZP) protein or peptide for use in preventing the increase of the number of animals in an animal population, to the use of a ZP protein or peptide in order to prevent the increase of the number o...
|
|
WO/2017/154865A1 |
The present invention provides an ameliorating agent for a female-specific physical and/or mental unpleasant symptom, which comprises γ-tocopherol and/or equol.
|
|
WO/2017/148975A1 |
The present invention relates to a composition comprising, as an antifungal agent, at least 2.1010 CFUs of Lactobacillus, and a sulphur compound, for use as a first line treatment for candidiasis infections and recurring candidiasis infe...
|
|
WO/2017/144925A1 |
The present invention relates to a topical composition which is mixture of natural ingredients of plant and animal origin, to the process of its preparation, to its use for treatment and/or prophylaxis of mastitis and/or edema in female ...
|
|
WO/2017/144393A1 |
The invention relates to bromodomain-protein-inhibiting, in particular BET-protein-inhibiting, and preferably BRD4-inhibiting 2-substituted 5-(phenyl)-1,2-dihydro-3H-3-benzazepine-3-carboxamide derivatives of general formula (I), where R...
|
|
WO/2017/137535A1 |
The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): (I) and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3- kinase...
|
|
WO/2017/139603A1 |
The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-t...
|
|
WO/2017/133337A1 |
The present invention provides a substituted benzimidazolone compound and a composition comprising the same. The present invention discloses a substituted benzimidazolone compound represented by formula (I) and a pharmaceutical compositi...
|
|
WO/2017/135805A1 |
The present invention relates to a composition made from extracts of ginger (Zingiber officinale), clove (Syzygium aromaticum), green tea (Camelia sinensis), pot marigold (Calendula officinalis), broccoli (Brassica oleracea italica) and ...
|
|
WO/2017/128932A1 |
The present invention discloses novel polymorphs I, II, and V of a [2-(4-(3-trifluoromethyl-benzyl)piperazin-1-yl)ethyl]-2,3-di
hydro-1H-benzimidazol-2-one and a preparation method and pharmaceutical application thereof. The polymorph I ...
|
|
WO/2017/130576A1 |
A medicinal composition comprising fulvestrant, castor oil, an aromatic carboxylic acid and at least one kind of polyhydric alcohol selected from between propylene glycol and 1,3-butylene glycol, wherein the content of ethanol is less th...
|
|
WO/2017/127675A1 |
The present invention provides a composition comprising HMB. Methods of administering HMB to an animal are also described. HMB is administered to modulate autophagy and lipophagy. HMB is also administered to treat, prevent, inhibit, slow...
|
|
WO/2017/126635A1 |
The purpose of the present invention is to provide a heterocyclic compound having an antagonistic activity on prostaglandin E2 (PGE2) receptor subtype 2. A compound represented by formula (I) [wherein each symbol is as defined in the des...
|
|
WO/2017/124826A1 |
Provided is a traditional Chinese medicinal product for treating a liver Qi stagnation type premenstrual tension and syndrome. The ingredients of the medicinal product comprise a Radix Bupleuri, a Radix Paeoniae Alba, a Radix Paeoniae Ru...
|
|
WO/2017/118641A1 |
The invention provides the L-valinate ester of a hydroxypropylthiazolidine carboxamide derivative of formula (I), (2S)-3-([1,1'-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1- phenylpropyl]-1,3-thiazolidine-2- carboxamide, as well as salts ...
|
|
WO/2017/118639A1 |
The invention provides pharmaceutical compositions comprising a compound of formula (I) or (II) and an additional therapeutic agent Also provided is the HCI salt and crystalline form of the compound of formula (I). The compounds inhibit ...
|
|
WO/2017/113101A1 |
Provided are a novel target CMKLR1 for female reproductive system diseases, and an application of CMKLR1 antagonists to preparation of drugs for preventing and/or treating female reproductive system diseases. Also provided is a pharmaceu...
|
|
WO/2017/110830A1 |
The present invention addresses the problem of finding an index of whether or not a combination therapy using L-asparaginase and an autophagy inhibitor is effective, and providing a cancer therapeutic agent for which the index can be use...
|
|
WO/2017/106814A1 |
Methods and compositions are provided for treating and preventing preterm labor using liposome encapsulated tocolytic agents, such as indomethacin. In certain aspects, targeted liposomes are provided that allow delivery of tocolytic agen...
|
|
WO/2017/104739A1 |
The present application discloses a therapeutic agent for breast cancer, which comprises 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4- yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N- methyl-1H-indole-1-carboxamide or a pharmacologically...
|
|
WO/2017/105512A1 |
Hormone formulations, dosage units including the hormone formulations, and methods of use, relate to a controlled release formulation, which includes hormones, e.g., progesterone. Formulations and methods are for controlling the reproduc...
|
|
WO/2017/101872A1 |
Application of plasminogen for treating cervical erosion; compared to existing medicines for treating cervical erosion, the present plasminogen or plasmin can promote inflammation repair of damaged mucosa.
|
|
WO/2017/098396A1 |
The object of the present invention is the synergistic combination of pyrrolidone carboxylic acid (PCA) and/or pharmaceutically acceptable salts thereof and hyaluronic acid and/or pharmaceutically acceptable salts thereof, for use in the...
|
|
WO/2017/092178A1 |
The present invention provides application of C-type natriuretic peptide in the preparation of a topical contraceptive and a sperm function test reagent. It is found in studies that at the time of ovulation, C-type natriuretic peptide is...
|
|
WO/2017/095261A1 |
The invention relates to the pharmaceutical industry and can be used for producing medicinal agents required in the treatment of diseases of the organs of the reproductive system (conditions of the mammary gland, womb, endometrium). A me...
|
|
WO/2017/090722A1 |
[Problem] The present invention addresses the problem of causing a gonadotropin to function with a low dose even when the gonadotropin is administered to fish, and preventing maturation of fish in aquaculture seedling production. [Soluti...
|
|
WO/2017/089475A1 |
The present invention relates in general terms to a pharmaceutical composition for topical application, comprising an effective combination of hyaluronic acid, beta-glucan, hydrolyzed sericin, and glycerophosphoinositol or a pharmaceutic...
|
|
WO/2017/089791A1 |
There is provided a nanoparticulate formulation comprising a mitochondrially-targeted antioxidant or ATP signalling inhibitor, as well as the use of such formulations in the treatment of conditions involving oxidative stress, such as pre...
|
|
WO/2017/091072A1 |
This invention relates to preparations comprising a butyrate salt for enteral administration for use in the treatment of conditions and diseases that are not diseases or conditions of the intestine and/or are associated with systemic inf...
|
|
WO/2017/085198A1 |
The present invention relates to derivativesof formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pha...
|
|
WO/2017/084612A1 |
Interferon vaginal effervescent capsules and a preparation method therefor. The interferon vaginal effervescent capsules consist of interferon freeze-dried powder, effervescent powder, and pharmaceutically acceptable accessories, the mas...
|
|
WO/2016/012632A9 |
The invention relates to tungsten (VI) salts used to treat infertility in a non-diabetic female mammal, for stimulating fertility and normal reproduction in a non-diabetic female mammal, or for increasing the effectiveness of an assisted...
|
|
WO/2017/083681A1 |
The presently-disclosed subject matter relates to crosslinkers, compositions, and methods for trapping a target of interest on a substrate of interest. The methods may be used to inhibit and treat pathogen infection and provide contracep...
|
|
WO/2017/079907A1 |
Disclosed is a kidney-tonifying medicinal liquor made of the following raw materials: 56-75 g of ginseng, 45-56 g of Achyranthes bidentata, 45-60 g of radix trichosanthis, 16-25 g of angelica, 12-24 g of fructus lycii, 45-60 g of cortex ...
|
|
WO/2017/073764A1 |
The present invention addresses the problem of providing a novel NK3-receptor selective ligand which is expected to have a highly-active/highly-selective and sustained effect in vivo. A compound represented by formula (I) X1-A2-A3-X4-X5-...
|
|
WO/2017/074266A1 |
The invention relates to glyceryl tridecanoate and uses thereof in treating endocrine disorders. More particularly, glyceryl tridecanoate may be used to treat hyper-androgenism, insulin resistance and infertility caused by, for example, ...
|
|
WO/2017/069793A1 |
The presently disclosed subject matter is directed to viscous vaginal pharmaceutical compositions comprising a water soluble gel, methods of making such compositions, and methods of using such compositions to treat vaginal dryness in a s...
|
